First‐line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non‐squamous non‐small cell lung cancer: Updated survival analysis of the <scp>ONO</scp>‐4538‐52/<scp>TASUKI</scp>‐52 randomized controlled trialHye Ryun Kim, Kazuhiko Nakagawa, Naoki Inui et al.|Cancer Medicine|2023Cited by 26
First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trialKi Hyeong Lee, Kazuhiko Nakagawa, Jong Seok Lee et al.|Lung Cancer|2025Cited by 9